Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 8/20 | 0.77 |
| ▸ | GCKR | Q14397 | 2/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15754 | 1.00 | GCK (0.77) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL18023 | 1.00 | GCK (0.77) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL16882 | 0.87 | GCK (1.00) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL12088782 | 0.87 | GCK (0.72) | GCKHSD11B1HTTALDH1A1HPGD | |
| SCHEMBL16921 | 0.83 | GCK (0.74) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL12078377 | 0.83 | GCK (0.74) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL16380 | 0.83 | GCK (0.74) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL17808 | 0.83 | GCK (0.74) | GCKGCKRHSD11B1HTTALDH1A1 | |
| SCHEMBL12089250 | 0.82 | GCK (0.66) | GCKHSD11B1HTTALDH1A1HPGD | |
| SCHEMBL12089257 | 0.82 | GCK (0.66) | GCKHSD11B1HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | claimed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GCK 2/4885GCKR 1/4885HSD11B1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.